By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Eisai Inc. 

100 Tice Boulevard

Woodcliff Lake  New Jersey  07677  U.S.A.
Phone: 201-692-1100 Fax: 201-692-1804

Headquartered in Woodcliff Lake, New Jersey, Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business. Eisai’s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Maryland, Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina. The company’s areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit

For more information about Eisai, please visit

Key Statistics

Ownership: Subsidiary

Web Site: Eisai Inc.
Employees: Approximately 2,600
Symbol: ESALF.PK


Company News
Helsinn Group And Eisai Inc. (ESALF.PK) Announce Inclusion Of AKYNZEO (netupitant/palonosetron) In ASCO Antiemetics Guideline Update 11/13/2015 7:29:56 AM
Eisai Inc. (ESALF.PK) Signs Research Collaboration Agreement With The Paoli Calmettes Institute 11/4/2015 6:27:02 AM
Eisai Inc. (ESALF.PK) And Arena (ARNA) Announce Presentation Of Lorcaserin Hcl Data At 2015 Annual Obesity Week Meeting 11/2/2015 6:43:51 AM
Eisai Inc. (ESALF.PK) Release: Halaven (eribulin mesylate) Injection Nominated For Best Pharmaceutical Agent Of The Year At The Prix Galien USA Awards 10/26/2015 11:08:56 AM
Results of Hematology/Oncology Pharmacy Association And Eisai Inc. (ESALF.PK) Survey Show 83 Percent Of Patients Receiving Chemotherapy May Be Unnecessarily Suffering From Chemotherapy-Induced Nausea And Vomiting 10/19/2015 10:15:37 AM
Eisai Inc. (ESALF.PK) Presents New Analyses Of Lenvatinib Data At The International Thyroid Congress (ITC) 10/15/2015 9:19:49 AM
Eisai Inc. (ESALF.PK) Release: New Myths And Truths About Thyroid Cancer Education Initiative Aims To Shine A Light On The Truths About Thyroid Cancer 9/15/2015 11:48:50 AM
Eisai Inc. (ESALF.PK) Announces FDA Acceptance Of NDA For The Review Of FYCOMPA (perampanel) Oral Suspension For Adjunctive Therapy In The Treatment Of Partial-Onset Seizures And Primary Generalized Tonic-Clonic Seizures In Patients With Epilepsy Age 12 And Older 9/14/2015 7:14:46 AM
Ivor Macleod Appointed Senior Vice President, Chief Financial Officer And Chief Compliance Officer Of Eisai Inc. (ESALF.PK) 6/1/2015 8:36:46 AM
Eisai Inc. (ESALF.PK) To Present New Data On Several Oncology Compounds At ASCO 2015 5/14/2015 11:18:17 AM